Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2019

Revenue Recognition

Disaggregation Of Revenue

In thousands of US dollars ($)		Three Months Ended March 31, 2019
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	68	$	—	$	68
Concentrate Products
Product Sales – Point-in-time		14,996		12,923		2,073
License Fee – Point-in-time		495		495		—
Total Concentrate Products		15,491		13,418		2,073
Net Revenue	$	15,559	$	13,418	$	2,141
		Three Months Ended March 31, 2018
Products By Geographic Area		Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	68		—	$	68
Concentrate Products
Product Sales – Point-in-time		14,376		12,472		1,904
License Fee – Point-in-time		504		504		—
Total Concentrate Products		14,880		12,976		1,904
Net Revenue	$	14,948	$	12,976	$	1,972

Contract Balances

In thousands of US dollars ($)	March 31, 2019		December 31, 2018
Receivables, which are included in "Trade and other receivables"	$	6,711	$	6,980
Contract liabilities	$	13,766	$	14,329